Abstract
Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are two types of pluripotent stem cells that hold great promise for biomedical research and medical applications. iPSCs were initially favorably compared to ESCs. This view was first based on ethical arguments (the generation of iPSCs does not require the destruction of an embryo) and on immunological reasons (it is easier to derive patient HLA-matched iPSCs than ESCs). However, several reports suggest that iPSCs might be characterized by higher occurrence of epigenetic and genetic aberrations than ESCs as a consequence of the reprogramming process. We focus here on the DNA integrity of pluripotent stem cells and examine the three main sources of genomic abnormalities in iPSCs: (1) genomic variety of the parental cells, (2) cell reprogramming, and (3) in vitro cell culture. Recent reports claim that it is possible to generate mouse or human iPSC lines with a mutation level similar to that of the parental cells, suggesting that “genome-friendly” reprogramming techniques can be developed. The issue of iPSC DNA integrity clearly highlights the crucial need of guidelines to define the acceptable level of genomic integrity of pluripotent stem cells for biomedical applications. We discuss here the main issues that such guidelines should address.
Keywords: Induced pluripotent stem cells, cell reprogramming, genetic abnormalities, pluripotency, DNA damage, genome integrity
Current Gene Therapy
Title:Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective
Volume: 13 Issue: 2
Author(s): Qiang Bai, Romain Desprat, Bernard Klein, Jean-Marc Lemaitre and John De Vos
Affiliation:
Keywords: Induced pluripotent stem cells, cell reprogramming, genetic abnormalities, pluripotency, DNA damage, genome integrity
Abstract: Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are two types of pluripotent stem cells that hold great promise for biomedical research and medical applications. iPSCs were initially favorably compared to ESCs. This view was first based on ethical arguments (the generation of iPSCs does not require the destruction of an embryo) and on immunological reasons (it is easier to derive patient HLA-matched iPSCs than ESCs). However, several reports suggest that iPSCs might be characterized by higher occurrence of epigenetic and genetic aberrations than ESCs as a consequence of the reprogramming process. We focus here on the DNA integrity of pluripotent stem cells and examine the three main sources of genomic abnormalities in iPSCs: (1) genomic variety of the parental cells, (2) cell reprogramming, and (3) in vitro cell culture. Recent reports claim that it is possible to generate mouse or human iPSC lines with a mutation level similar to that of the parental cells, suggesting that “genome-friendly” reprogramming techniques can be developed. The issue of iPSC DNA integrity clearly highlights the crucial need of guidelines to define the acceptable level of genomic integrity of pluripotent stem cells for biomedical applications. We discuss here the main issues that such guidelines should address.
Export Options
About this article
Cite this article as:
Bai Qiang, Desprat Romain, Klein Bernard, Lemaitre Jean-Marc and De Vos John, Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective, Current Gene Therapy 2013; 13 (2) . https://dx.doi.org/10.2174/1566523211313020003
DOI https://dx.doi.org/10.2174/1566523211313020003 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Anti-Cancer Agents in Medicinal Chemistry Recent Progress of Marine Polypeptides as Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Pyrrole-Based Macrocycles as Molecular Probes for Multimodal Imaging Techniques: Recent Trends
Current Organic Synthesis Polyoxometalates in Biomedicine: Update and Overview
Current Medicinal Chemistry Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Delivering the "Blueprints" or "DNA Repairing Kits" Instead of Drugs in the Treatment of Congenital Hemoglobinopathies
Current Organic Chemistry Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Possible Considerations for the Management of Turcot’s Syndrome?
Current Cancer Therapy Reviews